Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Drug side effects

Selective COX-2 inhibitors linked to worse outcomes after ischaemic stroke

COX-2 inhibitors linked to worse outcomes after ischaemic stroke (pictured)


Risk of ischaemic stroke is known to be increased by the use of selective cyclooxygenase-2 inhibitors

Non-steroidal anti-inflammatory drugs (NSAIDs) include non-selective and selective cyclooxygenase (COX)-2 inhibitors. Selective COX-2 inhibitors have been found to increase the risk of ischaemic stroke; new research suggests that these drugs also herald worse outcomes following ischaemic stroke.

Writing in Neurology (online, 5 November 2014)[1], Morten Schmidt, from Aarhus University Hospital Denmark, and colleagues report a cohort study involving 100,043 people admitted to hospital with a first stroke. Current use of a COX-2 inhibitor was associated with increased mortality at 30 days versus non-use (adjusted hazard ratio 1.19, 95% confidence interval 1.02–1.38). The risk increase was confined to older drugs such as etodolac and diclofenac.

“Our study adds to the increasing body of evidence concerning the vascular risk and prognostic impact associated with use of COX-2 inhibitors,” write Schmidt and co-authors.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067193

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.